RecruitingPhase 2NCT05516628

Deep, Multi-omics Phenotyping to Predict Response, Resistance and Recurrence to Adjuvant Atezolizumab Plus Bevacizumab in Resected Hepatocellular Carcinoma

Studying Combined hepatocellular carcinoma and cholangiocarcinoma

Last synced from ClinicalTrials.gov

ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
National Cancer Centre, Singapore
Principal Investigator
Pierce CHOW, MD, PhD
National Cancer Centre, Singapore
Intervention
Surgical Resection(procedure)
Enrollment
30 target
Eligibility
21-90 years · All sexes
Timeline
2023 – 2027

Study locations (6)

Collaborators

Singapore General Hospital · National University Hospital, Singapore · Changi General Hospital · Sengkang General Hospital · Tan Tock Seng Hospital · Singapore Clinical Research Institute · Genome Institute of Singapore · Institute of Molecular and Cell Biology of Singapore · Cancer Science Institute of Singapore · Duke-NUS Graduate Medical School · Singapore Phenome Centre · Nanyang Technological University · NMRC OF-LCG (OFLCG21Jun-0016)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT05516628 on ClinicalTrials.gov

Other trials for Combined hepatocellular carcinoma and cholangiocarcinoma

Additional recruiting or active studies for the same condition.

See all trials for Combined hepatocellular carcinoma and cholangiocarcinoma →

← Back to all trials